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s://Summary
BRCA1-associated protein-1 (BAP1) is a nuclear localized deubiquitylating enzyme that belongs to the ubiq-
uitin c-terminal hydrolase subfamily. The encoded protein is highly homologous between man and dogs, sug-
gesting a functional significance preserved by evolution. BAP1 has multiple properties, including tumour
suppressor activity. Loss of BAP1 function is implicated in the oncogenesis of several types of cancers including
uveal, mucosal and some cutaneous melanomas in humans, as well as in mesothelioma. In this study we inves-
tigate the significance of BAP1 in canine melanoma. Nuclear BAP1 protein was detected in five canine oral
melanoma cell lines using an antibody commonly used for analysis of human tissues. BAP1 loss of function mu-
tations often lead to loss of nuclear BAP1 (nBAP1) expression in humans; this is associated with a poorer prog-
nosis in uveal and mucosal melanoma. Therefore, as a prelude to a study evaluating the prognostic significance
of nBAP1 expression in dogs, immunohistochemistry (IHC) was used to assess cases of canine melanoma for
nBAP1 expression. In 89 cases where tumour cells were identified by melan-A labelling, 100% of tumour cells
were positive for nBAP1 expression, including eight uveal tract and 29 oral mucosal melanomas. This finding
indicates that BAP1 IHC cannot be used as a prognostic marker in canine uveal and mucosal melanoma.
Moreover, this observation suggests that either BAP1 has a different functional significance in canine mela-
noma or that loss of BAP1 function is achieved by a different route. This is a novel finding that warrants further
investigation to determine the comparative biological relevance.
 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords: BAP1; dog; immunohistochemistry; melanomaIntroduction
Ubiquitin (Ub) is an 8.5 kDa (kilodalton) protein
that ‘addresses’ proteins for degradation or trafficking
to a particular cellular site; additionally, it is involved
in regulating essential transcriptional factors such as
p53 (Hershko et al., 2000; Hochstrasser, 2000;
Pickart, 2001; Komander et al., 2009; Sun and Dai,
2014). Ubiquitylation involves a catalytic cascadeondence to: D.R. Killick (e-mail: drk@liverpool.ac.uk).
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CC BY licensby E1 (ubiquitin activating), E2 (ubiquitin
conjugating) and E3 (ubiquitin ligase) enzymes to
form an isopeptide bond between a lysine residue on
the target protein and Ub (Hochstrasser, 2000).
Modification can result in either mono-
ubiquitylation on the addition of a single Ub moiety
or poly-ubiquitylation on the addition of Ub chains
(Hochstrasser, 2000; Pickart, 2001; Komander,
2009; Komander et al., 2009). An important aspect
of ubiquitylation is the ability to reverse the process
by removing Ub moieties from the substrateuthors. Published by Elsevier Ltd. This is an open access article under the
e (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. (a) Comparative sequence information for canine and hu-
man BAP1 genes, mRNAs and proteins, showing that
canine and human BAP1 are highly homologous. (b) Sche-
matic diagram of human BAP1 protein (NP_004647.1)
featuring key functional domains and protein interaction
sites: ubiquitin C-terminal hydrolase (UCH) domain high-
lighting the catalytic triad (C91, H169, D184), host cell
factor-1 (HCF1) bindingmotif (HBM)anda nuclear local-
ization signal (NLS). (c) The canine BAP1 protein
(XP_541853.2) was aligned to the human sequence; amino
acid polymorphisms between human and canine BAP1 are
highlighted by arrows.
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Author's Personal Copythrough the action of deubiquitylating enzymes
(DUBs) (Nijman et al., 2005; Komander et al., 2009;
Clague et al., 2012; Abdul Rehman et al., 2016).
Depending on their catalytic domains, DUBs are
divided into six families (Nijman et al., 2005;
Komander et al., 2009; Clague et al., 2012; Abdul
Rehman et al., 2016). Five belong to the cysteine
protease family and include ubiquitin-specific prote-
ases (USPs), ubiquitin c-terminal hydrolases
(UCHs), ovarian tumour proteases (OTPs), Jose-
phins and MINDYs (Nijman et al., 2005; Komander
et al., 2009; Clague et al., 2012; Abdul Rehman
et al., 2016). The sixth family are zinc
metalloproteases known as JAB1/MPN/MOV34
(JAMMs) (Nijman et al., 2005; Komander et al.,
2009; Clague et al., 2012; Abdul Rehman et al., 2016).
BRCA1-associated protein-1 (BAP1) is a DUB that
belongs to theUCH subfamily (Jensen et al., 1998). In
humans, the BAP1 gene is located on chromosome
3p21.3. It encodes a protein consisting of 729 amino
acids (Fig. 1a). BAP1 consists of an N-terminal
UCH domain containing a catalytic triad, a host
cell factor-1 (HCF1) binding motif (HBM) and a nu-
clear localization signal (NLS) at the C-terminus
(Fig. 1b) (Jensen et al., 1998). Initially BAP1 was
identified in a yeast two-hybrid screen as a BRCA1-
binding protein due to its interaction with the
RING finger domain of this tumour suppressor
(Jensen et al., 1998), and was shown to have an inhib-
itory effect on the growth ofMCF7 breast cancer cells,
indicating that BAP1 acts as a tumour suppressor
gene (Jensen et al., 1998).
BAP1 is a nuclear localized DUB that interacts
with other proteins, often as part of a multiprotein
complex including HCF1 and ASXL1/2, which is
involved in regulating essential cellular processes
including transcription (Jensen et al., 1998; Dey
et al., 2012). BAP1 can remove multiple ubiquitin
molecules from substrates such as HCF1 to
stabilize them, and can remove single ubiquitin
molecules from histone H2A (Machida et al., 2009;
Misaghi et al., 2009; Sacco et al., 2015). BAP1 has
been shown to undergo both somatic and germline
mutation, the latter underpinning a familial
cancer predisposition syndrome (Abdel-Rahman
et al., 2011; Testa et al., 2011). BAP1 mutations
commonly lead to loss of its nuclear expression, as
nonsense or frameshift mutations lead to truncated
BAP1 protein lacking the NLS, and/or reduced
protein or mRNA stability. Such loss of nuclear
BAP1 is seen in a variety of human cancers, most
commonly malignant mesothelioma, uveal
melanoma, renal clear cell carcinoma and some
cutaneous melanomas (Harbour et al., 2010;
Abdel-Rahman et al., 2011; Carbone et al., 2012;Song et al., 2017). In humans, loss of nuclear
BAP1 (nBAP1) is common in oral mucosal and
uveal melanoma, but uncommon in cutaneous
melanoma (Kalirai et al., 2014; Song et al., 2017).
In uveal melanoma, mutation of the BAP1 gene is
associated with loss of nBAP1 expression, which
has been proposed as a surrogate clinical marker
(Kalirai et al., 2014; Koopmans et al., 2014). Loss
of nBAP1 (assessed by immunohistochemistry
[IHC]) is clinically significant in human oral
mucosal and uveal melanoma, where it is noted in
around 45% and 50% of cases, respectively, and
has been linked to a poor prognosis (Kalirai et al.,
2014; Song et al., 2017).
Melanoma is an aggressive tumour that affects both
humans and domestic dogs. In both species, mela-
noma may arise at a number of different anatomical
sites (Smith et al., 2002; Gillard et al., 2014;
Schiffman and Breen, 2015). Melanoma in dogs
develops in similar anatomical regions to the
tumour in man, albeit with different frequency at
each site. For example, cutaneous melanoma, the
most common location in man, is much less
common in dogs, with forms analogous to human
mucosal and acral lentiginous melanoma being
relatively more common (Smith et al., 2002; Gillard
et al., 2014; Schiffman and Breen, 2015).
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Author's Personal CopyThe aim of this study was to examine BAP1
involvement in canine cancers. We set out to charac-
terize canine BAP1 and to compare nBAP1 protein
expression in canine melanoma with that previously
described in human melanoma. Specifically, we hy-
pothesized that loss of nBAP1 in canine oral and uveal
melanoma would be associated with a poorer prog-
nosis. As a prelude to the prognostic study we evalu-
ated nBAP1 expression in a tissue microarray
(TMA) composed of canine melanoma from a variety
of sites.Materials and Methods
Alignment Analysis
To determine the degree of homology between canine
(gene ID 484737) and human (gene ID 8314) BAP1
mRNA and protein, sequences were acquired from
the National Center for Biotechnology Information
(www.ncbi.nlm.nih.gov) and aligned using CLC
Main workbench system (version 7.6.4, Qiagen,
Denmark).Cell Culture
Human mesothelioma cell lines MSTO-211H and
NCI-H28 were cultured as described by Sacco et al.
(2015). Canine malignant melanoma cell lines from
five dogs were a generous gift from Dr. M. S. Kent
at the University of California Davis, Davis, Califor-
nia, USA. UCDK9M3 andUCDK9M4 are from pri-
mary oral mucosal melanomas, UCDK9M2 and
UCDK9M5 are from lymph node metastases of oral
mucosal melanoma and UCDK9M1 was derived
from a skin metastasis of an oral mucosal melanoma
(Aina et al., 2011). These cell lines were cultured in
Dulbecco’s modified Eagle’s medium (DMEM)
with 10% heat inactivated fetal bovine serum and
1% non-essential amino acids. Cells were confirmed
as mycoplasma free and were passaged regularly by
washing with phosphate buffered saline, detaching
with trypsin for 2e3 min at 37C and reseeding in
fresh media. All cells were grown in a humidified
incubator at 37C and 5% CO2.RNA Interference
UCDK9M4 cells were seeded at a density of
1.2  105/well into a six-well plate. The following
day, they were transfected with 40 nM siRNA:
hs_BAP1_2, hs_BAP1_5 (Qiagen) or a non-
targeting siRNA control (siC) using Oligofectamine
(Invitrogen, Carlsbad, California, USA) following
the manufacturer’s protocol. After 72 h, transfected
cells were harvested for protein extraction and evalu-ation by immunoblotting. The siRNAs were designed
to target human BAP1; however, hs_BAP1_2 and
hs_BAP1_5, have 100% and 79% homology with
the canine sequence, respectively.
Immunoblotting
Whole cell protein extracts were prepared by scraping
cells directly into hot Laemmli buffer (50 mM Tris
pH 6.8, 2% sodium dodecyl sulphate [SDS], 10%
glycerol) and incubated at 110C for 10 min with vor-
texing every 2 min. The protein concentration of each
sample was established using a bicinchoninic acid
assay (Thermo Scientific, Rockford, Illinois, USA).
Protein extracts were prepared in Laemmli buffer
and denatured at 98C for 5 min before electrophor-
esing on 10% SDS polyacrylamide gel electrophoresis
gels and subsequent transfer onto BiotraceNT mem-
brane (VWR International Ltd., Lutterworth,
UK). Membranes then underwent blocking, washing
and primary antibody incubation overnight at 4C,
followed by washing (in Tris-buffered saline with
0.1% Tween-20) and secondary antibody incubation
for 1 h at room temperature. Primary antibodies used
were mouse anti-human BAP1 (C-4, Santa Cruz
Biotechnology, Santa Cruz, Californian, USA) and
mouse anti-human b-actin (Abcam, Cambridge,
UK). To visualize proteins, donkey anti-mouse IR-
Dye secondary antibodies were used for detection
(LI-COR Biosciences UK Ltd., Cambridge, UK) us-
ing a LI-COR Odyssey Classic blot imager and im-
ages were evaluated using Image Studio (LI-
COR).
Immunofluorescence
Canine melanoma cells (UCDK9M1, UCDK9M3
andUCDK9M5) were seeded onto autoclaved cover-
slips in six-well plates at 1.5 105/well. The following
day, medium was aspirated and the cells were fixed in
4% paraformaldehyde, quenched with ammonium
chloride and permeabilized with 0.1% triton prior
to blocking and incubation with the mouse anti-
human BAP1 primary antibody (Santa Cruz).
Alexa-Fluor 488-conjugated secondary anti-mouse
antibody (Molecular Probes, Eugene, Oregon,
USA) was used. Coverslips were mounted on Moviol
(Sigma-Aldrich, St. Louis, Missouri, USA) supple-
mented with 40,6-diamidino-2-phenylindole (DAPI;
Sigma-Aldrich) at 1 in 10,000 dilution where indi-
cated. Cells were imaged using a Nikon Eclipse Ti
(CFI Plan Apochromat 40 NA 0.95, WD 0.14 mm
or CFI Super Plan Fluor ELWD ADM 20C NA
0.45, WD 8.2e6.9) microscope (Nikon, Tokyo,
Japan) and data analysed using Fiji software
(Schindelin et al., 2012).
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Canine melanoma tissue samples were sourced from
clinical cases submitted to Bridge Pathology. In
each case, a diagnosis of melanoma was made by a
board-certified veterinary pathologist. Cases were re-
viewed to determine whether they were suitable for
IHC.Construction of a Tissue Micro-array and
Immunohistochemistry
A tissue micro-array (TMA) containing triplicate
0.6 mm tissue cores from each case was constructed
using the manual tissue micro-arrayer (Beecher In-
struments, Sun Prairie, Wisconsin, USA) as described
byKalirai et al. (2014). Samples included in the TMA
were grouped as follows: digit, skin, oral, uveal and
periocular. Sections (4 mm) were cut from the TMA
block and mounted on slides.
The TMA sections underwent antigen retrieval us-
ing the Dako pretreatment module (Agilent Technol-
ogies LDA UK Ltd., Stockport, UK); slides were
incubated in a high-pH bath containing EnVision
FLEX target retrieval solution (Tris/EDTA buffer
pH 9.0) at 96C for 20 min. IHC was performed on
the Dako Autostainer PLUS machine, using the
Dako Envision FLEX Kit (Agilent) according to
the manufacturer’s instructions. Slides were incu-
bated with the following antibodies for 30 min: mouse
anti-human melan-A (clone A103, Agilent) at a con-
centration of 1 mg/ml to aid identification of mela-
noma cells; and mouse anti-human BAP1 at a
concentration of 1 mg/ml. Positive labelling was ‘visu-
alized’ with 3,30 diaminobenzidine for BAP1 and
amino-ethyl carbazole (Vector Laboratories, Peter-
borough, UK) for melan-A. The sections were coun-
terstained with haematoxylin. Human pancreas was
used as a positive control to demonstrate nuclear
BAP1 (nBAP1) localization and human ocular mela-
noma tissue was used as a positive control for melan-
A. Additional sections were treated with mouse IgG1
isotype control at the same concentration as the BAP1
and melan-A primary antibodies and served as nega-
tive controls.Scanning and Scoring
The TMA slides were scanned using an Aperio Im-
agescope (Leica Biosystems, Wetzlar, Germany) and
assessed for nBAP1 protein expression by three inde-
pendent observers (NJ, HK and SC). The tissue sam-
ples were given a final score according to the
percentage of tumour nuclei that expressed nBAP1
protein across the TMA cores (Kalirai et al., 2014).Ethical Approval
Ethical approval for this project was granted by the
University of Liverpool Committee to the Faculty of
Health and Life Sciences on Research Ethics (Veter-
inary Science) e project number VREC360.Results
Canine and Human BAP1 are Highly Homologous
Initially, alignments of protein (canine XP_541853.2,
human NP_004647.1) and mRNA (canine
XM_541853.5, human NM_004656.3) were gener-
ated (Fig. 1a) and the homology between human
and canine BAP1 was evaluated (Fig. 1b). The hu-
man mRNA and predicted canine mRNA were high-
ly similar, and the predicted canine BAP1 protein was
virtually identical to that of the human BAP1 at 98%
amino acid homology. Alignment analysis showed
that those amino acids differing between human
and canine BAP1 clustered in three areas; notably
these were all outside the major functional domains,
which were conserved (Figs. 1b and c).BAP1 Antibody Validation and BAP1 Expression in Canine
Melanoma Cell Lines
In this study we used a BAP1 antibody, which is
commonly reported in the literature as detecting
BAP1 in human cell lines and human tissue samples
(Kalirai et al., 2014; Sacco et al., 2015). The epitope
for this antibody is largely conserved between
human and canine BAP1 sequences, suggesting
likely cross reactivity (Figs. 1b and c). To confirm
this, and to examine BAP1 expression in the canine
melanoma cell lines, immunoblotting was performed
(Fig. 2a). The human mesothelioma cell lines
MSTO-211H (BAP1 positive) and NCI-H28 (BAP1
negative) (Sacco et al., 2015) were used as controls
for BAP1 immunoreactivity, and b-actin was used
as a loading control. A strongly immunoreactive
band of around 85 kDa, the same molecular weight
as human BAP1, was detected in each of the five
canine oral melanoma cell lines examined.
To confirm the identity of this immunoreactive
band, we ‘knocked down’ BAP1 in the UCDK9M5
cell line, using two BAP1 siRNA sequences indepen-
dently (Fig. 2b). These siRNAs are designed against
the human sequence and targeted regions with high
sequence homology between the two species (siRNA
HS_BAP1_2 is an exact match); both siRNAs re-
sulted in 80% reduction in the BAP1 immunoreactive
band comparedwith a non-targeting siRNA. In order
to confirm that BAP1 localized to the nuclei of canine
melanoma cell lines, we used immunofluorescence
Fig. 2. (a) BAP1 expressionwas assessed by immunoblotting usingwhole cell extracts fromfive caninemelanoma cell lines and thehuman
mesothelioma cell lines MSTO-211H (BAP1 positive) and NCI-H28 (BAP1 negative); b-actin was used as a loading control. (b)
Knockdown using two BAP1 targeting siRNAs leads to reduced expression of BAP1 protein in UCDK9M5 canine melanoma
cells. (c) Three canine oral melanoma cell lines (UCDK9M1, UCDK9M3 and UCDK9M5) were immunolabelled using the
same human anti-BAP1 antibody and counterstained with DAPI; canine BAP1 demonstrated a predominantly nuclear localiza-
tion. Bar, 120 mm.
Table 1
Distribution of melanoma sites, age and gender
Anatomical site (number of
cases)
Median age (Range) Gender
Male Female
Digit (19) 9y 7m (6y 2me13y) 16 3
Skin (22) 8y 7m (1y 6me13y 3m) 12 10
Oral (28) 11y 8m (8ye16y) 17 11
Uveal (8) 10y 3m (5ye13y) 3 5
Periocular (13) 9y 5m (6ye13y) 6 7
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Author's Personal Copy(Fig. 2c). In the three cell lines examined, BAP1
showed a predominantly nuclear localization, with
exclusion from the nucleoli and some diffuse cyto-
plasmic labelling. Together these data suggest that
oral canine melanoma cell lines express nBAP1 pro-
tein, and that this anti-human BAP1 antibody can
be used for IHC in canine melanoma tissue.
Histological Assessment of the Tissue Microarray Sections
One-hundred and five samples were retrieved
initially; however, following HE staining, 15 samples
were excluded due to inadequate preservation or
excessive pigmentation that would have interfered
with IHC. Therefore, 90 samples (Table 1) were ar-
rayed on the TMA.
Clinical Data
The clinical characteristics of the 90 canine samples
included in the study are summarized in Table 1.They comprised of 37 females and 53males. The cases
came from animals of 25 different breeds and included
17 crossbred dogs; breeds represented by more than
five individuals included: cocker spaniel (n ¼ 8),
German shepherd dog (n ¼ 6), golden retriever
(n ¼ 7), Labrador retriever (n ¼ 15), Rottweiler
(n ¼ 7). The median age at diagnosis was 9 years.
These dogs were diagnosed with melanoma, which
Table 2
Frequency of nuclear BAP1 labelling
Anatomical site Melan A-positive
tumour cells
100% of tumour
cells nBAP1 positive
Digit 18/19 + 1 equivocal 18/19
Skin 22/22 22/22
Oral 28/28 28/28
Uveal 8/8 8/8
Periocular 13/13 13/13
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digits (n ¼ 19), skin (n ¼ 22), oral cavity (n ¼ 28),
uveal tract (n¼ 8) and periocular tissue (n¼ 13; seven
eyelid and six conjunctival) based on histopatholog-
ical examination by a board-certified veterinary
pathologist (TS) (Fig. 3a).
Assessment of BAP1 Expression by Immunohistochemistry
Melan-A labelling was performed in order to confirm
the diagnosis of melanoma as well as to identify the
location of the melanoma cells in the tissue. In some
cases, melanoma cells made up the majority of cells
in the tissue core (Fig. 3b, digital and uveal). In other
cases, there were islands or sporadic melanoma cells
throughout the core (Fig. 3b, skin and oral). On
initial labelling, three cases were only focally faintly
positive for melan-A and four were melan-A negative.
The seven cases with either missing tumour or little/
no melan-A labelling, underwent sectioning of the
whole tissue block and were re-labelled in the study.
Of these seven cases, six labelled positively for
melan-A, while one case remained negative for
melan-A expression. All cases were included in the
subsequent analysis.
Of the 90 canine samples with confirmed mela-
noma, 89 showed positive nBAP1 labelling (Fig. 3c,
Table 2). However, one case labelled only very faintly
focally positive for nBAP1 and interestingly this was
the same case that labelled negatively for melan-A.
In addition, strong to weak cytoplasmic BAP1
(cBAP1) expression was also seen in each case, consis-Fig. 3. Representative images are shown for four cores from the follow
8 magnification, insets are at40. (a) HE-stained TMA secti
sections used to identify melanocytic tumour cells. (c) BAP1 imtent with the immunofluorescence data for canine
melanoma cell lines (Fig. 2c). Overall, with the excep-
tion of the single melan-A negative case, strong
nBAP1 labelling was seen in each of the samples
drawn from the most common anatomical sites to be
affected by melanoma in the dog (Fig. 3c).
Discussion
Loss of function of the tumour suppressor gene BAP1
is believed to play a role in the progression of several
human cancers including uveal and oral mucosal mel-
anoma and some cutaneous melanomas (Jensen et al.,
1998; Andrici et al., 2016). Dogs are also affected by
each of these melanoma types (Gillard et al., 2014).
Here we highlight the marked homology between hu-
man and canine BAP1, showing that complete
sequence identity is conserved within the major func-
tional domains. Although alignments reveal several
amino acid polymorphisms, these are tightly clustered
outside the functional domains, and at present theing anatomical sites: oral, digit, skin and uveal. Main images are at
ons used to determine tumour regions. (b)Melan-A labelled TMA
munoreactivity in TMA sections.
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the canine BAP1 protein is unknown. Detailed mech-
anistic analysis will be needed to assess whether these
sequence differences confer any differential BAP1
functionality across species.
In this study, 90 canine melanomas obtained from
the digits, skin, oral cavity, uveal tract or the perioc-
ular region were analysed for nBAP1 expression using
IHC. Lack of nBAP1 protein expression is associated
with loss of function mutations of BAP1 and is com-
mon in several human cancers such as uveal and
oral mucosal melanoma and malignant mesotheli-
oma. Functional studies have demonstrated that loss
of IHC expression for nBAP1 is a useful marker of
clinical behaviour in these tumours (Kalirai et al.,
2014; Andrici et al., 2016; Song et al., 2017). In this
study of 90 melanoma cases, the 89 cases that were
melan-A positive labelled with 100% positivity for
nBAP1 protein expression within the tumour cells.
We have not ascertained why the remaining case
from a digital melanoma had only equivocal nBAP1
expression; however, this case also labelled negatively
for melan A. This likely indicates a technical issue as
this sample underwent decalcification, which is
known to reduce antibody binding (Ramos-Vara
and Miller, 2011).
This study was performed in the same laboratory
using the same technique as a previous study that re-
ported that loss of nBAP1 is associated with a poorer
outcome in human uveal melanoma (Kalirai et al.,
2014). Moreover, the work presented here was per-
formed contemporaneously with, and with the same
methodology as, a follow-up study (to Kalirai et al.,
2014) in this laboratory, which confirmed the prog-
nostic significance of loss of nBAP-1 in human uveal
melanoma (Farquhar et al., 2018). The possibility
that the unexpected results of this study relate to
experimental methodology can therefore be excluded.
The results of this study indicate that the incidence
of nBAP1 protein loss in canine melanoma differs
from that reported in human melanoma, specifically
uveal and oral mucosal melanoma where loss of
nBAP1 protein expression is reported in around
50% of cases (Kalirai et al., 2014; Song et al., 2017).
This loss is correlated strongly with a poor prognosis
(Kalirai et al., 2014; Song et al., 2017). Furthermore,
the absence of nBAP1 protein expression is
indicative of the presence of a BAP1 mutation in
human cancers such as malignant mesothelioma
and uveal melanoma, as well as Spitz melanoma
(Wiesner et al., 2012; Yoshikawa et al., 2012; Song
et al., 2017). A more recent study has shown that
both nBAP1 and cBAP1 expression were absent in
70% of uveal melanoma patients who developed
metastasis (Kalirai et al., 2014). As a result, severalstudies have proposed routine inclusion of IHC for
BAP1when investigating uveal melanoma andmalig-
nant mesothelioma (Koopmans et al., 2014;
Cigognetti et al., 2015; Andrici et al., 2016).
Almost nothing is known about the biology of BAP1
(and DUBs more generally) in dogs, and while one
possibility is that BAP1 is not of significance in canine
melanoma, another is that canine melanoma reaches
the same functional outcome by a different route not
detectable by our approach. For example, it has
been shown that retention of nBAP1 protein expres-
sion does not necessarily exclude the possibility that
the BAP1 gene may harbour loss of function mutations
(Ventii et al., 2008). Ventii et al. (2008) demonstrated
that missense mutations within the catalytic domain of
BAP1 reduced tumour suppressor activity, but not
protein expression, in a human NSCLC cell line.
This highlights the fact that the presence of nBAP1 pro-
tein expression does not rule out the possibility of ab-
normalities in BAP1 function per se. Of note,
although BAP1 knockout mice develop a myelodys-
plastic disorder with features of chronic myelomono-
cytic leukaemia (CMML), in human CMML,
mutation ofBAP1 is rare but that of the BAP1 interact-
ing protein ASXL1 is very common (Dey et al., 2012).
In conclusion, the present study has validated re-
agents for investigation of BAP1 in canine cancer. Us-
ing these reagents we undertook the first evaluation of
BAP1 in dogs. We investigated nBAP1 expression by
IHC in a panel of canine melanoma samples from
different anatomical sites; this was planned as a pre-
lude to a study investigating the prognostic signifi-
cance of BAP1 in canine melanoma. Unexpectedly,
all of the samples expressed nBAP1, therefore we
conclude that BAP1 IHC cannot be used for prognos-
tication in canine melanoma. This is a novel finding
and warrants further investigation as part of the
ongoing effort to identify new biomarkers and treat-
ments for canine melanoma and development of
canine melanoma as a model for the disease in man.
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